Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
SERA PROGNOSTICS, INC. Chief Executive Officer Zhenya Lindgardt reported an open-market sale of Class A common stock. The filing shows 20,755 shares sold at a weighted average price of $2.08 per share. The footnotes explain this was a mandated “sell to cover” transaction to satisfy tax withholding on vesting restricted stock units, not a discretionary sale. After the transaction, Lindgardt directly holds 871,999 shares.
Sera Prognostics Chief Financial Officer Austin Aerts reported an open-market sale of 5,440 shares of Class A common stock at a weighted average price of $2.08 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations triggered by vesting of restricted stock units under a mandatory “sell to cover” election, and were not a discretionary trade. After this transaction, Aerts directly holds 303,227 shares, indicating he retains a substantial equity position in the company.
SERA filed a Form 144 notice reporting sales and vesting-related activity in Class A Common stock. The excerpt lists a Restricted Stock Unit Vesting event dated 06/09/2026 and two sales reported for the three months ended in 03/10/2026 and 03/11/2026, showing 22,639 and 2,973 shares respectively. The filing names Zhenya Lindgardt as a seller and lists Morgan Stanley Smith Barney LLC as a broker on the record.
SERA reported a notice of proposed sale of Class A Common shares in a Form 144 referencing 06/09/2026. The filing lists Restricted Stock Unit Vesting as the securities type and shows past sales by Austin Aerts on 03/09/2026, 03/10/2026, and 03/11/2026 with the numeric entries shown in the excerpt.
Sera Prognostics director Sandra AJ Lawrence sold 1,560 shares of Class A common stock in an open-market transaction. The sale on June 8, 2026 was executed at a weighted average price of $2.15 per share, with individual trades ranging from $2.10 to $2.23. After the sale, Lawrence directly holds 16,473 shares. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2025.
Sera Prognostics, Inc. held its 2026 annual stockholder meeting by live audio webcast. Of 38,190,966 Class A common shares eligible to vote as of April 13, 2026, 25,773,203 shares were represented, forming a 67.5% quorum.
Stockholders elected Kim Kamdar, Ph.D. and Sandra A. J. Lawrence as Class II directors to serve until the 2029 annual meeting, with Kamdar receiving 9,749,623 votes for and Lawrence 12,483,966 votes for, plus broker non-votes in each case. They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 24,917,046 votes for and 856,113 against.
SERA PROGNOSTICS, INC. director Elliott Jeffrey Thomas filed a Form 4 reporting no stock transactions or holdings in this filing. The summary data show zero purchases, zero sales, zero derivative exercises, and no gifts, tax withholdings, or restructuring-related transfers.
Sera Prognostics General Counsel Benjamin Jackson acquired additional company stock through an employee plan. On May 29, Jackson acquired 5,000 shares of Class A common stock at $1.84 per share under Sera Prognostics’ 2021 Employee Stock Purchase Plan for the purchase period from December 1, 2025 to May 29, 2026. Following this acquisition, he directly holds 163,935 shares. The transaction is classified as a grant or award-type acquisition and is exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating it is a routine, compensation-related purchase rather than a discretionary open-market trade.
Sera Prognostics, Inc.’s Chief Commercial Officer, Dyaarl Lee Anderson Jr., acquired 3,168 shares of Class A Common Stock at $1.84 per share. These shares were purchased through the company’s 2021 Employee Stock Purchase Plan for the purchase period from December 1, 2025 to May 29, 2026.
Following this transaction, he directly holds 82,737 shares of Class A Common Stock. The filing characterizes the event as a grant, award, or other acquisition exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating a routine employee share purchase rather than an open-market trade.